{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.26","value":"-0.10"},{"groupId":"OG001","spread":"0.26","value":"-0.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. A unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Scores range from 0 (death) to 1 (perfect health), but scores \\<0 are possible based on the algorithm.","dispersionType":"Standard Deviation","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"MEAN","populationDescription":"All randomized participants with baseline and 30-day follow-up data.","reportingStatus":"POSTED","timeFrame":"Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)","title":"Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}